| Application: | 10625, Determining the effect of immune-mediated disease (IMD) genetic risk variants on secondary health outcomes and their interaction with environmental factors |
| Title: | Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity |
| Size: | 1.9 MB |
| Archived: | 9 Dec 2020 |
| Stability: | Complete |
| Personal: | No individual-level data |
Return 3052
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Notes
In this study we characterised the effects of a low frequency variant in the TYK2 gene known to be protective to over 10 immune-mediated diseases. By interrogating data available through the UK Biobank we found that people carrying the protective TYK2 variant were no more likely to have serious infections or to develop cancer than people without the variant; suggesting TYK2 as a potential therapeutic target with few side effects.Application 10625
Determining the effect of immune-mediated disease (IMD) genetic risk variants on secondary health outcomes and their interaction with environmental factors
Immune-mediated diseases (IMDs), such as multiple sclerosis, comprise a clinically heterogeneous group of disorders affecting ~3-5% of individuals of European ancestry. Our understanding of the exact mechanisms that lead to these conditions remains limited, but scientific progress has shown that both genetic and environmental factors play important roles. We aim to integrate and analyse the extensive genetic, clinical and epidemiological data available through the UK Biobank, in order to identify key shared but also disease-specific mechanisms that may be targeted for therapeutic benefit. One of the aims of the UK Biobank is to improve prevention, diagnosis and treatment of a wide range of illnesses. For many of these illnesses, and in particular for IMDs, genetic and environmental factors play an important role in disease susceptibility. A first step towards meeting this aim for IMDs is to elucidate how these risk factors interact, thereby altering immunological responses and promoting disease development. The proposed research aims to integrate UK Biobank epidemiological, clinical and genetic data to identify parameters for disease risk prediction and diagnosis, and disease mechanisms that may be amenable to drug targeting. Through recent genomic studies an extensive catalogue of genetic variants that influence IMD susceptibility has been constructed. Many of these variants affect risk to multiple conditions, and in some instances have opposing effects on different disorders. For most variants, however, the mechanisms by which they mediate their effects are unknown. The extensive data sets available through the UK Biobank provide a unique opportunity to perform a comprehensive computational assessment of how genetic and environmental factors influence not one but a breadth of different immunological conditions and clinical phenotypes. The results of these analyses will be integrated with laboratory-based studies. In order to perform the required computational analyses and to integrate them with laboratory-based findings, this project requires data regarding lifestyle and epidemiological factors, clinical and para-clinical information, and genetic data. In particular, we are requesting information on all individuals with available genetic data, and with the possibility of updating access to resources, as more individuals are genotyped. For those individuals with available genetic data, we would request access to known diagnoses of IMDs and relevant environmental exposures from the clinical records, such as smocking and known episodes of viral and bacterial infections. No samples are requested.
| Lead investigator: | Professor Lars Fugger |
| Lead institution: | University of Oxford |
1 Publication
| Pub ID | Title | Author(s) | Year | Journal |
|---|---|---|---|---|
| 3053 | Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity | Dendrou CA et al. | 2016 | Sci Transl Med |
Enabling scientific discoveries that improve human health